Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06975371 · ClinicalTrials.gov registry record
Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i
A clinical trial, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- 1,415
- Enrollment target
NCT06975371 is a clinical trial that has completed, run by Daiichi Sankyo. The registered enrollment target is 1,415 participants.
The verdict
NCT06975371 has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- 1,415 participants
- Enrollment target
Study Summary
This study aims to assess the treatment patterns and real-world outcomes of HR+/HER- metastatic breast cancer patients who have progressed on 1L ET + CDK4/6i and started a second line (2L) treatment within a real-world cohort in the United States Flatiron Health Database.
Interventions
- OTHER No drug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,415 participants |
| Start Date | 2025-04-14 |
| Est. Completion | 2025-08-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06975371
The ClinicalTrials.gov registry entry for NCT06975371 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,415 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No drug is the first listed.
NCT06975371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06975371 about?
NCT06975371 is a clinical study titled "Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i". This study aims to assess the treatment patterns and real-world outcomes of HR+/HER- metastatic breast cancer patients who have progressed on 1L ET + CDK4/6i and started a second line (2L) treatment within a real-world cohort in the United States Flatiron Health Database.
What is the current status of trial NCT06975371?
This trial is currently completed. The enrollment target is 1,415 participants. The study started on 2025-04-14. Estimated completion is 2025-08-05.
What interventions are being tested in trial NCT06975371?
The interventions under investigation include: No drug (OTHER).
Who is sponsoring clinical trial NCT06975371?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.